Kiniksa Pharmaceuticals International, plc (KNSA)

From the record

Kiniksa Pharmaceuticals International, plc's filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Kiniksa Pharmaceuticals International, plc's 5 filed years say what it did: revenue went from $39 million in fiscal 2021 to $678 million in fiscal 2025, up 104.8% a year; it rose in 4 of 4 years; it never fell from a peak; net income was positive in 3 of 5 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Kiniksa Pharmaceuticals International, plc's diluted share count grew about 3.9% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 89 sales (88 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Kiniksa Pharmaceuticals International, plc earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 79 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 26 cents per dollar of assets, and net share issuance: its share count grew 10.6% over the year (the filed statements).

From the record

Kiniksa Pharmaceuticals International, plc's standing among 315 graded names in its industry family: revenue of $678 million in fiscal 2025 ranks in the top 16% by size; a net margin of 8.7% ranks in the top 17%; revenue growth of 45.4% a year over the last 3 filed years ranks in the top 25% (its annual reports).

From the record

Kiniksa Pharmaceuticals International, plc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Patel, Sanj K (CHAIRMAN & CEO, as filed), filing under that title since 2018-05-23, 8.5 years (top 21% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 8.5 years (top 17%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Kiniksa Pharmaceuticals International, plc's room to grow, from the newest filed statements (fiscal 2025): cash of $166 million against no long-term debt tagged leaves 21.7% of its assets as net cash, bottom 43% of its family; cash from operations less capital spending is 20.1% of revenue (top 12%); a gross margin of 88.5% (top 18%); research spending of 14.3% of revenue (bottom 18%) (its annual report).

From the record

Kiniksa Pharmaceuticals International, plc's growth drivers, from the filed years to fiscal 2025: revenue grew 45.4% a year over the last three filed years against 104.8% over all 5, slowing (bottom 10% of its family); the newest year grew 60.1% (top 23%); research spending grew 13.9% a year (top 33%); capital spending grew 146.2% a year (top 5%) (its annual reports). Kiniksa Pharmaceuticals International, plc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Kiniksa Pharmaceuticals International, plc's newest year against its own record: revenue of $678 million in fiscal 2025 came in 15.5% above the $587 million its prior three years' pace pointed to (top 29% of its family); net income of $59 million against a prior three-year average of $51 million (bottom 49%); a net margin of 8.7% against 26.1% before (bottom 26%) (its annual reports).